Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies

Madhav Madurantakam Royam, Chellan Kumarasamy, Siddhartha Baxi, Ajay Gupta, Nachimuthu Ramesh, Gothandam Kodiveri Muthukaliannan, Rama Jayaraj

Research output: Contribution to journalReview article

Abstract

Background: Findings from observational clinical studies examining the relationship between biomarker expression and theranosis in colorectal cancer (CRC) have been conflicting.

Objective: We conducted this systematic review and meta-analysis to summarise the existing evidence to demonstrate the involvement of microRNAs (miRNAs) in chemoresistance and sensitivity in CRC through drug genetic pathways.

Methods: Using PRISMA guidelines, we systematically searched PubMed and Science Direct for relevant studies that took place between 2012 and 2017. A random-effects model of meta-analysis was applied to evaluate the pooled effect size of hazard ratios (HRs) across the included studies. Cochran’s Q test and the I 2 statistic were used to detect heterogeneity. A funnel plot was used to assess potential publication bias.

Results: Of the 4700 studies found, 39 studies comprising 2822 patients with CRC met the inclusion criteria. The included studies used one or a combination of 14 chemotherapy drugs, including 5-fluorouracil and oxaliplatin. Of the 60 miRNAs, 28 were associated with chemosensitivity, 20 with chemoresistance, and one with differential expression and radiosensitivity; ten miRNAs were not associated with any impact on chemotherapy. The results outline the importance of 34 drug–regulatory pathways of chemoresistance and sensitivity in CRC. The mean effect size was 0.689 (95% confidence interval 0.428–1.110), indicating that the expression of miRNAs decreased the likelihood of death by about 32%.

Conclusion: Studies have consistently shown that multiple miRNAs could act as clinical predictors of chemoresistance and sensitivity. An inclusion of supplementary miRNA estimation in CRC routine practice needs to be considered to evaluate the efficacy of chemotherapy after confirming our findings with large-scale prospective cohort studies. PROSPERO registration number: CRD42017082196.

Original languageEnglish
Pages (from-to)65-82
Number of pages18
JournalMolecular Diagnosis and Therapy
Volume23
Issue number1
Early online date6 Feb 2019
DOIs
Publication statusPublished - Feb 2019

Fingerprint Dive into the research topics of 'Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies'. Together they form a unique fingerprint.

  • Cite this